Oncology Data Advisor is excited to be launching our new podcast series, "Exploring Artificial Intelligence in Oncology." Hosted by Waqas Haque, MD, MPH, Member of the Oncology Data Advisor Fellows Forum, this series will delve into the burgeoning roles and uses of AI in cancer care, from pathology to toxicity risk prediction to treatment recommendations and beyond.

Exploring Artificial Intelligence in Oncology

In this first episode of Oncology Data Advisor’s new podcast series, “Exploring Artificial Intelligence in Cancer Care,” Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients’ probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost’s novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.

Predicting Immune-Related Adverse Events Through Machine Learning With Dr. Ofer Sharon of OncoHost

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.

Streamlining the Pathology Workflow Through AI: Waqas Haque and Leif Honda of TriMetis

In this installment of Oncology Data Advisor's Exploring AI in Oncology series, Dr. Waqas Haque speaks with Dr. Shaalan Beg, an Adjunct Associate Professor at the University of Texas (UT) Southwestern, who is spearheading efforts to decentralize clinical trials in oncology and expand access for eligible patients. Dr. Beg describes the tools that are currently in development for decentralizing trials, including the use of artificial intelligence (AI), natural language processing, and telehealth. Additionally, he shares his perspectives on transitioning to a career in industry.

Expanding Clinical Trial Access With Decentralization and Technology: Waqas Haque and Shaalan Beg

In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. 

Check out the discussion to learn more about: 
•	Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies
•	Every Cure’s mission to unlock the potential of drugs that are already on the market
•	Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets
•	Barriers in drug repurposing, including clinical validation and eventual approval
•	The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research
•	How to develop efficient clinical trials without a large sample size
•	The future of AI-enabled drug discovery in oncology 
•	And more!

Every Cure: Unlocking Drug Potential With Artificial Intelligence With Waqas Haque and Tracey Sikora

This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. 

Check out the episode to hear more about: 
•	Qure.ai’s mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI
•	Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps
•	Qure.ai’s end-to-end AI-powered solutions for early lung cancer detection and care
•	The efficacy of these solutions and how they can be used in the clinic
•	The lung cancer portfolio that Qure.ai showcased at ASCO
•	Other innovations coming down the pipeline
•	And more!

Qure.ai: Improving Early Lung Cancer Detection Through AI with Ranjana Devi and Waqas Haque, MD, MPH

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 2 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies"

Don't forget to claim your credit after the episode!

Click on the link to claim your credit for module 2: bit.ly/43VoFNP

Additional Advances in Systemic Mastocytosis With Mariana Castells, MD, PhD + Module 2

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 1 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies"

Don't forget to claim your credit after the episode!

Click on the link to claim your credit for module 1: bit.ly/3Y3ivHM
Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP

Additional Advances in Systemic Mastocytosis Research and Clinical Trials With Mariana Castells, MD, PhD + Module 1

Christoph U. Correll, MD, Professor of Psychiatry and Molecular Medicine at the Zucker School of Medicine at Hofstra/Northwell and Chair of Child and Adolescent Psychiatry at Charité University in Berlin, is currently chairing i3 Health’s four-part educational activity, Schizophrenia Update: Navigating the Latest in Research and Treatment. In this interview, he shares recent updates in schizophrenia research and explains why education is so critical for clinicians to optimize their patients’ outcomes.

Click here to listen to the full activity podcasts! 

Module 1: https://bit.ly/3JsEYKf
Module 2: https://bit.ly/436dYa5
Module 3: https://bit.ly/47fkz4p
Module 4: https://bit.ly/4oflWWZ

Additional Insights in Schizophrenia Research and Clinical Trials With Christoph U. Correll, MD

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai 

In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

Improving Early and Equitable Lung Cancer Detection With Sybil: Mary Pasquinelli, DNP, FNP-BC, CTTS, and Waqas Haque

Time is running out to access this essential CME/NCPD-approved podcast! Join renowned dermatology experts Dr. Peter A. Lio and Dr. Linda F. Stein Gold as they dive into the latest evidence and best practices for treating atopic dermatitis in children and adolescents. With new therapies rapidly changing the treatment landscape, this podcast delivers the practical insights you need to confidently diagnose, evaluate, and manage pediatric atopic dermatitis.

Don’t miss your chance to:

-Get up to speed on novel and emerging therapies, including nonsteroidal topicals, JAK inhibitors, and monoclonal antibodies
-Learn how to recognize key clinical features that inform the differential diagnosis
-Discover strategies to optimize outcomes and quality of life for your young patients

This activity is expiring soon—listen now to stay current and earn credit before it’s gone!

Click here to claim your CME/NCPD credit: https://bit.ly/4nGZhBG

EXPIRING SOON! Best Practices & Breakthroughs in Pediatric Atopic Dermatitis

Time is running out to access this essential CME/NCPD-approved podcast! Join renowned dermatology experts Dr. Peter A. Lio and Dr. Linda F. Stein Gold as they dive into the latest evidence and best practices for treating atopic dermatitis in children and adolescents. With new therapies rapidly changing the treatment landscape, this podcast delivers the practical insights you need to confidently diagnose, evaluate, and manage pediatric atopic dermatitis.

Don’t miss your chance to:

-Get up to speed on novel and emerging therapies, including nonsteroidal topicals, JAK inhibitors, and monoclonal antibodies
-Learn how to recognize key clinical features that inform the differential diagnosis
-Discover strategies to optimize outcomes and quality of life for your young patients

This activity is expiring soon—listen now to stay current and earn credit before it’s gone!

Click here to claim your CME/NCPD credit: bit.ly/4nGZhBG

LAST CHANCE – Expires November 21!

Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.


Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T

EXPIRING SOON! Diagnosis and Management of Dedifferentiated Liposarcoma

LAST CHANCE – Expires November 21!

Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.

Listen now and earn 0.5 CME credit: bit.ly/49GyP5T

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO

Oncology Data Advisor®

Related tracks